CLEC12A and acute myeloid leukemia: Other studies have investigated novel therapeutic strategies to kill AML cells by combination of NK cells, and trispecific killer engager (TriKE) molecules targeting CLEC12A, the AML mice treated with CLEC12A TriKE had significantly less tumor burden compared to tumor alone or tumor with NK cells (120) (Figure 2b).